3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof
Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , having a structure selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
4. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
5. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
6. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
7. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 7 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.